Lilly loses Andrew Hotchkiss to Immunocore

The UK biotech that brands itself the world’s leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, has named Andrew Hotchkiss as its chief commercial officer.

Mr Hotchkiss joins from US pharma major Eli Lilly, where he held a number of global leadership positions across multiple therapeutic areas and geographies, including international business unit leader for oncology and president of biomedicines business units, Australia, Canada and Europe.